RCKT
HEALTHCARERocket Pharmaceuticals Inc
$3.86+0.32 (+9.04%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RCKT Today?
No stock-specific AI insight has been generated for RCKT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.19$7.39
$3.86
Fundamentals
Market Cap$401M
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding109.2M
RCKT News
20 articles- Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush SaysYahoo Finance·May 8, 2026
- Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent ProgressYahoo Finance·May 7, 2026
- 3 Promising Penny Stocks With Market Caps Up To $600MYahoo Finance·May 6, 2026
- Rocket to sell PRV for $180m to advance gene therapy pipelineHospitalmanagement·Apr 29, 2026
- Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherYahoo Finance·Apr 28, 2026
- RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseYahoo Finance·Mar 30, 2026
- Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIYahoo Finance·Mar 29, 2026
- Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene TherapyYahoo Finance·Mar 29, 2026
- Promising Penny Stocks To Consider In March 2026Yahoo Finance·Mar 27, 2026
- Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I KidsMarketbeat·Mar 27, 2026
- Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIProactive Investors·Mar 27, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investor Concerns Linger Amid Middle East ConflictYahoo Finance·Mar 27, 2026
- Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)Yahoo Finance·Mar 27, 2026
- Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advancesProactive Investors·Mar 3, 2026
- RCKT's Q4 Loss Narrower Than Estimated, Pipeline in FocusYahoo Finance·Feb 27, 2026
- Rocket Pharmaceuticals: Q4 Earnings SnapshotYahoo Finance·Feb 26, 2026
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent ProgressYahoo Finance·Feb 26, 2026
- Rocket Pharmaceuticals to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 23, 2026
- Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector RecoveryYahoo Finance·Feb 19, 2026
- Undervalued Penny Stocks To Consider In January 2026Yahoo Finance·Jan 26, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$3.54
Day High$0.00
Day Low$0.00
52 Week High$7.39
52 Week Low$2.19
52-Week Range
$2.19$7.39
$3.86
Fundamentals
Market Cap$401M
P/E Ratio—
EPS$-2.01
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume3.1M
Avg Volume (10D)—
Shares Outstanding109.2M
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—